ClariVest Asset Management’s Vir Biotechnology VIR Stock Holding History

ClariVest Asset Management’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-77,054	Closed	-$1.89M	–	850
2023 Q2	$1.89M	Sell	77,054 -11,678	-13%	-$293K	0.09%	138
2023 Q1	$2.06M	Buy	88,732 +52	+0.1%	+$1.33K	0.09%	170
2022 Q4	$2.25M	Sell	88,680 -241	-0.3%	-$5.91K	0.11%	149
2022 Q3	$1.72M	Sell	88,921 -17,296	-16%	-$440K	0.08%	179
2022 Q2	$2.71M	Sell	106,217 -37,500	-26%	-$875K	0.12%	149
2022 Q1	$3.7M	Buy	143,717 +46,574	+48%	+$1.38M	0.15%	148
2021 Q4	$4.07M	Buy	+97,143	New	+$3.81M	0.13%	156
2021 Q3	–	Sell	-8,896	Closed	-$420K	–	831
2021 Q2	$420K	Buy	8,896 +3	+0%	+$136	0.01%	447
2021 Q1	$456K	Sell	8,893 -2,768	-24%	-$149K	0.02%	425
2020 Q4	$311K	Sell	11,661 -16,033	-58%	-$521K	0.01%	459
2020 Q3	$951K	Buy	+27,694	New	+$1.19M	0.03%	307

Other funds holding VIR

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

ClariVest Asset Management's VIR Position: Q3 2023 in Review

ClariVest Asset Management sold out of Vir Biotechnology (VIR) in Q3 2023, closing a stake of 77,054 shares — an estimated $1.89M sold.

ClariVest Asset Management first reported a position in VIR in Q3 2020 and held it in 11 quarters. The position peaked at $4.07M in Q4 2021. 214 funds tracked by Wall St. Rank hold VIR as of Q3 2023.

ClariVest Asset Management reported no remaining Vir Biotechnology position as of Q3 2023 after selling out during the quarter.
ClariVest Asset Management sold 77,054 Vir Biotechnology shares in Q3 2023, an estimated $1.89M.
ClariVest Asset Management first reported a position in Vir Biotechnology in Q3 2020 and held it in 11 quarters.
ClariVest Asset Management's Vir Biotechnology position peaked at $4.07M in Q4 2021.
214 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2023.

Based on ClariVest Asset Management's 13F filing for Q3 2023, filed 13 Nov 2023.